5. Analysis of differences between doses calculated and measured in-vivo during irradiation with mantle fields  by Litoborski, M.
28
the growth of newly formed hybridomas. 15 ,39-41
The work performed on this aspect in the 1980s
has culminated with the discovery that a charac-
terized plasmacytoma/hybridoma growth fac-
tor42,43 was identical to interleukin-6 (IL-6), which
is a pleiotropic cytokine active on the differentia-
tion of B lymphocytes.44 The importance of adding
exogenous IL-6 (or medium conditioned by IL-6-
producing cells such as the P388D1 monocytic
cells) to hybridoma cultures was further shown by
the observation that IL-6 preferentialIy promoted
the survival of the hybridomas secreting MoAbs.45
The dependence to IL-6 is rapidly lost during pro-
longed cultures.
Another important aspect of the culture of newly
formed hybridomas is the quality of the fetal calf
serum used. The quality parameters are not yet
defined, but it is elear that certain serum lots are
much better than others for promoting the growth
of newly formed B celI hybridomas. The relative
performance of the serum lots should be tested in a
fusion experiment rather than by their effect on the
growth of myeloma ar established hybridoma
cells. 45
Source of Antigen-Activated B Lymphocytes
lt is quite elear that the activation of antigen-
specific B lymphocytes is a parameter that is much
more important than the immortalization step. As a
matter of fact, myeloma cells fuse efficiently only
with activated B lymphocytes that are at a differ-
entiation stage somewhere between resting B lym-
phocytes and fully differentiated plasma cells. 46
Preparation of B lymphocytes at the appropriate
differentiation stage is relatively easy in the murine
system but represents a major problem in human
hybridoma technology.
Murine Lymphocytes
The routine protocol for preparing murine B
lymphocytes suitable for efficient fusion is to im-
munize a group of mice with the antigen of inter-
est, determine the serum antibody level in the in-
dividual animals, select the animaI showing the
highest antigen-specific response, and recover the
activated spleen cells 3 or 4 days after a last injec-
tion ("boost") of antigen. 15 This basic protocol
has been used since the original description of the
hybridoma technology and has been successful
thousands of times. However, it is not unerring,
and all investigators in this field have experienced
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failures most probably caused by the absence of
antigen-activated lymphoblasts in the spleen cells
recovered on the fusion day. Many of these fail-
ures may be caused by the induction in the animal
immune system of a suppression/tolerance state
preventing the final activation step. The possible
reasons for this phenomenon are diverse and may
include such parameters as seasonal variations
(springtime is not very good) and the pampering of
animals. One measurable parameter that may
cause this phenomenon is the immunization proto-
col; we have observed that hyperimmunization of
mice was not advisable for the preparation of a
high number of antihuman red blood cells Mo-
Abs.47 Another parameter that is relevant to trans-
fusion medicine concems the optimal time period
between the final antigen boost and the fusion ex-
periment. We have previously shown that the op-
timal period may be shorter (2 instead of 3 to 4
days) for some antigens such as the blood group A
antigen.48
Although several factors influencing the yield of
antigen-activated B cells are still not well defined,
it is elear that most problems can probably be
avoided by using groups of mice and various im-
munization schedules.
Human Lymphocytes
The lack of a suitable and reproducible source of
antigen-activated human B lymphocytes has been
and still is the major difficulty in the preparation of
human MoAbs by the hybridoma technology. The
reasons for this are multiple. Obviously, humans
cannot be immunized with antigens of interest.
Furthermore, the peripheral blood was unti! re-
cently (discussed subsequently) the only routinely
available source of human B cells (at least to blood
banks).
In vitro immunization and activation. In the
1980s, much effect was made in the development
of conditions favoring the in vitro immunization
and activation of human peripheral blood lympho-
cytes (PBL). Such systems have been de-
scribed49 ,50 and human MoAbs have been prepared
from the B cells activated in vitro. 51-54 However, it
is generally recognized that the efficiency of such
systems is low compared with murine in vivo sys-
tems. In transfusion medicine-related work, sev-
erallaboratories (mostly in Europe) have been suc-
cessful in the preparation of human anti-Rh
antibodies by using in vitro-activated (pokeweed
end ot December 2000 (each patient had made
measurement once or two or three times).
Semiconductor detectors (with OPD 510 by
Scanditronix) were used during in-vivo dosimetry.
Doses were calculated and measured in (1) the
centre ot the irradiation tield; (2) supraclavicular
region; (3) mediastinum; (4) lower edge ot the
tield and (5) necko Patients were irradiated at
various accelerators, most ot them at Neptun with
photons 9 MeV.
Results: Ali patients were divided into three
groups. The criterion of inclusion was the per
cent difference between calculated and
measured doses average for all dosimetrical
points. The ranges for the groups were: 0-5%, 5-
10% and over 10 %. The mean per cent
differences in the first group of 43 patients was
3.1 %, in second of 27 patients - 6.3%, and in
third of 6 patients - 17.6% respectively. There
was no elear reason, beside an aeeidental error
why for the eertain patient difference was much
larger than for the another. Mean difference tor
all groups was equal to 5.3%.
In the table mean per cent differences
between doses calculated and measured and
their standard deviations (SD) in the whole
group ot patients are shown tor central axis,
mediastinum and supraclavicular region.
central axis mediastinum
supraclavicular
region
Mean diff. SD Mean diff. SD Mean diff. SD
1.5% 4.1% -0.3% 4.6% 2.0% 5.7%
Conclusion: Mean difference in the whole
group of patients showsgood agreement
between pre-calculated and measured doses,
especially for three clinically important regions
(table). It is accompanied by low standard
deviation which is an indicator ot smali deviations
between doses inside the whole group.
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THE TECHNIQUE OF TOTAL BODY
IRRADIATION APPLlED IN THE ST.
LESZCZYŃSKI MEMORIAL HOSPITAL
IN KATOWICE
A.Kawa - Iwanicka, M. Dybek, T. Iwanieki,
W. Łobodziec, A. Radkowski
Radiotherapy Department of the Hospital -
Memorial Sto Leszczyński, Katowice
At the Sto Leszczyński Memorial Hospital in
Katowice a moditication ot TBI technique was
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prepared. For this a special two variant ot body
trame - one tor treatment planning and an
another one for treatment delivery - was made.
The total dose of 12 - 15 Gy (in lung not more
than 9 Gy) was delivered in six fraction of 15 MV
photons, produced in Primus Iinear accelerator,
for 3 consecutive days. Patient was treated by a
combination ot tields: lateral - set at SSO ot 330
cm and AP/PA - set at 135 cm. The dose-rate
measured at 10 cm in a water phantom for
(ateral tields was 4,3 cGy/min., and tor AP/PA
fields 23,6 cGy/min. Lung shields were made
from wood alloy and their shape was carried out
from computerized tomograph scans (CT). For
each patient a set of computerized tomograph
scans was prepared. Patient during the eT was
laying in supine position in the body trame made
of 1 cm thick plexi plates. On the walls of that
body frame a special marks ot tin materiał were
inserted. These marks allow to reproduce both -
the same patient position during the irradiation
and also in the treatment planning system
HELAX. Position of shields before AP/PA
fraction was determined by means ot HELAX,
and then shields were fastened to plexi trays
inserted in the head of Primus. Lung was also
shielded during one lateral fraction and the
shape ot the shield was carried· out on a
simulator. The volume between the patient and
walls of the body frame was fulfilled by bolus
(bags with rice) to get a homogenous dose
distribution. The electron boost to the thorax wall
(shielded for 15 MV photons) was delivered with
a 6 or 9 MeV electron beam.
The percentage deviation of dose, for all 9
irradiated patients, calculated at ten anatomical
points representative of the body anatomy, was
in the limit -0,4% to +13% (excluded in lung)
trom the dose delivered to PC (reterence point:
1/2 AP and 1/2 lateral dimension at 1/2 of
patient length in irradiation position). The in vivo
measurements carried out by means ot
MOSFET detectors confirmed that accuracy.
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IMRT NEW STANDARDS IN
TREATMENT PLANNING
A. Grządziel, K. Ślosarek, R. Rutkowski,
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Technological advances in medical imaging
have prompted accelerator manutactures to
produce more and more advanced treatment
delivery systems capable to preeise shape the
dole distribution.
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